Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Zelmac DTC Ads To Emphasize Relief Of Abdominal Pain, Bloating

Executive Summary

Consumer ads for Novartis Zelmac will emphasize relief of abdominal pain and bloating in addition to constipation, VP and General Manager-U.S. Operations Kurt Graves suggested during an R&D meeting in Basel, Switzerland Dec. 6.

You may also be interested in...



Novartis Zelmac Trade Name Could Be Changed Following FDA Discussions

Novartis' discussions with FDA regarding use of the trade name Zelmac for the irritable bowel syndrome therapy (tegaserod) may lead to the company launching the product under a different name.

Novartis Zelmac Trade Name Could Be Changed Following FDA Discussions

Novartis' discussions with FDA regarding use of the trade name Zelmac for the irritable bowel syndrome therapy (tegaserod) may lead to the company launching the product under a different name.

SmithKline IBS Research Is One Of Nine Divestments Under FTC Order

SmithKline Beecham is required to divest its rights to Alizyme's irritable bowel syndrome therapy renzapride under the FTC consent order allowing the GlaxoSmithKline merger despite Glaxo's recent withdrawal of Lotronex.

Related Content

UsernamePublicRestriction

Register

PS037022

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel